No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
The lab will facilitate the development of herbal and natural-based solutions
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Subscribe To Our Newsletter & Stay Updated